Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
Núria M. Pastor‐Soler, Hui Li, Jessica Pham, Daniel Rivera, Pei‐Yin Ho, Valeria Mancino, B. Saitta, Kenneth R. Hallows
Abstract
Metformin treatment improved ADPKD disease severity in a relevant, slowly progressive ADPKD mouse model that recapitulates a PKD-associated PKD1 mutation. Relative to controls, metformin reduced kidney weight/body weight, cystic index and BUN levels, while improving GFR, blood pressure and anemia. Metformin also reduced key inflammatory and injury markers, along with cell proliferation markers. These findings suggest several beneficial effects of metformin in this ADPKD mouse model, which may help inform new ADPKD therapies in patients.
Topics & Concepts
MetforminAutosomal dominant polycystic kidney diseaseMedicinePolycystic kidney diseaseInternal medicineDiseasePKD1EndocrinologyDiabetes mellitusGenetic and Kidney Cyst DiseasesGenetic Syndromes and ImprintingHedgehog Signaling Pathway Studies